Iodine 125 prostate brachytherapy: Prognostic factors for long-term urinary, digestive and sexual toxicities

被引:5
|
作者
Doyen, J. [1 ]
Chamorey, E. [2 ]
Ali, A. Mohammed [1 ]
Ginot, A. [1 ]
Ferre, M. [1 ]
Castelli, J. [1 ]
Quintens, H. [3 ]
Amiel, J. [3 ]
Hannoun-Levi, J. -M. [1 ]
机构
[1] Ctr Antoine Lacassagne, Dept Radiotherapie Oncol, F-06189 Nice, France
[2] Ctr Antoine Lacassagne, Unite Stat Med, F-06189 Nice, France
[3] CHU Pasteur, Serv Urol, F-06002 Nice 1, France
来源
CANCER RADIOTHERAPIE | 2009年 / 13卷 / 08期
关键词
Complications; Brachytherapy; Prostate cancer; 125; Iodine; Implant; Prognostic factors; LATE RECTAL FUNCTION; QUALITY-OF-LIFE; INTERSTITIAL BRACHYTHERAPY; (125)IODINE IMPLANTATION; BIOCHEMICAL OUTCOMES; I-125; BRACHYTHERAPY; PREDICTIVE FACTORS; SEED IMPLANTATION; TUMOR-CONTROL; MORBIDITY;
D O I
10.1016/j.canrad.2009.08.144
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. - For patients with good urinary function and presenting with a low risk prostate cancer, prostate brachytherapy using iodine implants represents one of the techniques of reference. This retrospective analysis investigates urinary (U), digestive (D) and sexual (S) toxicities and their prognostic factors of duration. Material and methods. - From August 2000 to November 2007, 176 patients presenting with prostate adenocarcinoma underwent interstitial brachytherapy. Urinary, digestive and sexual toxicities were classified according to Common toxicities criteria for adverse events, version 3.0 (CTCAE V3.0). For each toxicity (U. D, S), the number of complications U (dysuria, nicturia ...), D (proctitis, diarrhea ...) and S (sexual dysfunction, loss of libido ....) was listed and analyzed according to criteria related to the patient, implant, dosimetric data and characteristics of the toxicity. Prognostic factors identified in univariate analysis (UVA) (Log Rank) were further analyzed in multivariate analysis (MVA) (Cox model). Results. - With a median follow-up of 26 months (1-87), 147 patients (83.5%) presented urinary toxicities. Among them, 29.5% (86 patients) and 2.4% (seven patients) presented grade 2 and 3 U toxicity respectively. In UVA, urinary grade toxicity greater than or equal to 2 (p=0.037), the presence of initial U symptoms (p=0.027) and more than two urinary toxicities (p=0.00032) were recognized as prognostic factors. The number of U toxicities was the only prognostic factor in MVA (p=0.04). D toxicity accounted for 40.6% (71 patients). Among them, 3% (six patients) were grade 2. None were grade 3. Two factors were identified as prognostic factors either in UVA and MVA: the number of D toxicities greater than or equal to 2 (univariate analysis: p=0.00129, multivariate analysis: p=0,002) and age less than or equal to 65 years (univariate analysis: p=0,004, multivariate analysis: p=0,007). Eighty-three patients (47.4%) presented a sexual toxicity: 26.9% (49 patients) and 5% (nine patients) were scored as grade 2 and 3 respectively. A number of seeds greater than 75 (p=0.032) and S grade greater than or equal to 2 (p < 0.0001) were recognized as prognostic factors in UVA. S grade was the only prognostic factor in MVA (p=0.0015). Conclusion. - The duration of U, D and S toxicity is strongly correlated with a high number of toxicities and the grade of toxicity. This analysis allows for better information given to the patient regarding the duration of the post-treatment complications. (C) 2009 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:721 / 730
页数:10
相关论文
共 50 条
  • [31] Prostate brachytherapy: Prognostic factors for acute urinary retention, sexual function and results, from 243 cases
    Rempelakos, Apostolos
    Palantzas, Athanasios
    Georgakopoulos, John
    Georgalis, A.
    Arvanitakis, T.
    Katsilieris, J.
    JOURNAL OF ENDOUROLOGY, 2007, 21 : A214 - A214
  • [32] Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy
    Eriguchi, Takahisa
    Yorozu, Atsunori
    Kuroiwa, Nobuko
    Yagi, Yasuto
    Nishiyama, Toru
    Saito, Shiro
    Toya, Kazuhito
    Hanada, Takashi
    Shiraishi, Yutaka
    Ohashi, Toshio
    Shigematsu, Naoyuki
    BRACHYTHERAPY, 2016, 15 (03) : 288 - 295
  • [33] Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients
    Tanaka, Tomoki
    Yorozu, Atsunori
    Sutani, Shinya
    Yagi, Yasuto
    Nishiyama, Toru
    Shiraishi, Yutaka
    Ohashi, Toshio
    Hanada, Takashi
    Saito, Shiro
    Toya, Kazuhito
    Shigematsu, Naoyuki
    BRACHYTHERAPY, 2018, 17 (05) : 799 - 807
  • [34] Long-term urinary function after transperineal brachytherapy for patients with large prostate glands
    Sherertz, T
    Wallner, K
    Wang, H
    Sutlief, S
    Russell, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (05): : 1241 - 1245
  • [35] Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy
    Nag, S
    DeHaan, M
    Scruggs, G
    Mayr, N
    Martin, EW
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (03): : 736 - 744
  • [36] Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy
    Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, Netherlands
    不详
    Int. J. Radiat. Oncol. Biol. Phys., 4 (1072-1079):
  • [37] INFLUENCE OF DOSE ON RISK OF ACUTE URINARY RETENTION AFTER IODINE-125 PROSTATE BRACHYTHERAPY
    Roeloffzen, Ellen M. A.
    Battermann, Jan J.
    van Deursen, Marijke J. H.
    Monninkhof, Evelyn M.
    Visscher, Mareije I.
    Moerland, Marinus A.
    van Vulpen, Marco
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1072 - 1079
  • [38] Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer
    Onishi, Kenta
    Tanaka, Nobumichi
    Miyake, Makito
    Nakai, Yasushi
    Anai, Satoshi
    Torimoto, Kazumasa
    Yamaki, Kaori
    Asakawa, Isao
    Hasegawa, Masatoshi
    Fujii, Tomomi
    Konishi, Noboru
    Fujimoto, Kiyohide
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2019, 14 : 51 - 58
  • [39] Predictive Factors for Urinary Morbidity after I-125 Prostate Brachytherapy
    Senzaki, T.
    Fukumori, T.
    Komori, M.
    Yamamoto, Y.
    Yamaguchi, K.
    Nakatsuji, H.
    Izaki, H.
    Takahashi, M.
    Kanayama, H.
    UROLOGY, 2012, 80 (03) : S292 - S292
  • [40] Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study
    Salem, N
    Simonian-Sauve, M
    Rosello, R
    Alzieu, C
    Gravis, G
    Maraninchi, D
    Bladou, F
    RADIOTHERAPY AND ONCOLOGY, 2003, 66 (02) : 159 - 165